Table 1 Demographics of the study cohorts
Parameter | Training cohort (n = 61) | Reproducibility cohort (n = 173) | Radiogenomic cohort (n = 87) | TCGA cohort (n = 1010) |
|---|---|---|---|---|
Age (years) | ||||
 Median | 48 (29.7–72.4) | 47.8 (26.7–68.8) | 52 (29–82) | 59 (26–90) |
 Mean ± SD | 48.1 ± 9.8 | 47.7 ± 8.8 | 53.3 ± 11.3 | 58.9 ± 13.2 |
Race | ||||
 Asian | 3 (5) | 7 (4) | 0 | 61 (6) |
 Black or African-American | 3 (5) | 30 (17) | 4 (5) | 180 (18) |
 White | 47 (77) | 135 (78) | 82 (94) | 675 (67) |
 Unknown or others | 8 (13) | 1 (1) | 1 (1) | 94 (9) |
Oestrogen receptor status | ||||
 Positive | 28 (46) | 97 (56) | 75 (86) | 733 (73) |
 Negative | 20 (33) | 74 (43) | 12 (14) | 226 (22) |
 Indeterminate | 0 | 0 | 0 | 2 (0) |
 Unknown | 13 (21) | 2 (1) | 0 | 49 (5) |
Progesterone receptor status | ||||
 Positive | 22 (36) | 81 (47) | 69 (79) | 630 (63) |
 Negative | 26 (43) | 90 (52) | 18 (21) | 326 (32) |
 Indeterminate | 0 | 0 | 0 | 4 (0) |
 Unknown | 13 (21) | 2 (1) | 0 | 50 (5) |
Human epidermal growth factor receptor 2 status | ||||
 Positive | 14 (23) | 102 (59) | 15 (17) | 149 (15) |
 Negative | 31 (51) | 69 (40) | 46 (53) | 518 (51) |
 Equivocal | 0 | 0 | 19 (22) | 172 (17) |
 Unknown | 16 (26) | 2 (1) | 7 (8) | 171 (17) |
Histological type | ||||
 Infiltrating ductal | 37 (60) | N/A | 75 (86) | 709 (70) |
 Infiltrating lobular | 12 (20) | N/A | 10 (12) | 193 (19) |
 Others | 12 (20) | N/A | 2 (2) | 107 (11) |
 Unknown | 0 | N/A | 0 | 1 (0) |
Follow-up (years) | ||||
 Median | 5.39 (0.28–9.84) | 3.91 (0.51–6.76) | 3.48 (0.37–9.40) | 1.15 (0.03–19.36) |
 Mean ± SD | 4.77 ± 2.749 | 3.85 ± 1.46 | 3.93 ± 2.22 | 2.37 ± 2.94 |
Recurrence | ||||
 Event | 23 (38) | 49 (28) | 5 (6) | 97 (10) |
 No event | 38 (62) | 124 (72) | 67 (77) | 674 (67) |
 Unknown | 0 | 0 | 15 (17) | 239 (23) |
Death | ||||
 Event | N/A | 32 (18) | 1 (1) | 104 (10) |
 No event | N/A | 138 (80) | 86 (99) | 906 (90) |
 Unknown | N/A | 3 (2) | 0 | 0 |